Perflutren Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

Start your free 7-Day Trial! Book a demo to explore our global patent data.

It is formulated by 1 pharmaceutical company such as LANTHEUS MEDCL. It is marketed under 1 brand name, including DEFINITY RT. Available in 1 different strength, such as 13.04MG/2ML (6.52MG/ML), and administered through 1 route including INJECTABLE;INTRAVENOUS.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 1 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...
watch_later Watch: autorenew Loading watch analysis...
rocket_launch Opportunity: autorenew Loading opportunity analysis...
flag
gavel
calendar_today
calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
✓ Latest exclusivity data and extensions
Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength Route of Administration Companies Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

Patent Number Publication Date Legal Status Patent Expiry Date
{"application_id":"62464","ingredient":"PERFLUTREN","trade_name":"DEFINITY RT","family_id":"c93a03be982a40738428","publication_number":"US10022460B2","cleaned_patent_number":"10022460","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-12-28","publication_date":"2018-07-17","legal_status":"Granted"} US10022460B2 Molecular Formulation 17 Jul, 2018 Granted 28 Dec, 2035
{"application_id":"62447","ingredient":"PERFLUTREN","trade_name":"DEFINITY","family_id":"c93a03be982a40738428","publication_number":"US10583207B2","cleaned_patent_number":"10583207","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-12-28","publication_date":"2020-03-10","legal_status":"Granted"} US10583207B2 10 Mar, 2020 Granted 28 Dec, 2035
{"application_id":"62465","ingredient":"PERFLUTREN","trade_name":"DEFINITY RT","family_id":"c93a03be982a40738428","publication_number":"US11395856B2","cleaned_patent_number":"11395856","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-12-28","publication_date":"2022-07-26","legal_status":"Granted"} US11395856B2 Molecular Formulation 26 Jul, 2022 Granted 28 Dec, 2035
{"application_id":"62420","ingredient":"PERFLUTREN","trade_name":"DEFINITY","family_id":"aa0a3b1a16d34e1ca1af","publication_number":"US10583208B2","cleaned_patent_number":"10583208","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-03-16","publication_date":"2020-03-10","legal_status":"Granted"} US10583208B2 10 Mar, 2020 Granted 16 Mar, 2037
{"application_id":"62422","ingredient":"PERFLUTREN","trade_name":"DEFINITY","family_id":"aa0a3b1a16d34e1ca1af","publication_number":"US11266750B2","cleaned_patent_number":"11266750","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-03-16","publication_date":"2022-03-08","legal_status":"Granted"} US11266750B2 08 Mar, 2022 Granted 16 Mar, 2037
{"application_id":"62404","ingredient":"PERFLUTREN","trade_name":"DEFINITY","family_id":"aa0a3b1a16d34e1ca1af","publication_number":"US9789210B1","cleaned_patent_number":"9789210","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-03-16","publication_date":"2017-10-17","legal_status":"Granted"} US9789210B2 17 Oct, 2017 Granted 16 Mar, 2037
{"application_id":"62426","ingredient":"PERFLUTREN","trade_name":"DEFINITY","family_id":"aa0a3b1a16d34e1ca1af","publication_number":"US11529431B2","cleaned_patent_number":"11529431","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-03-16","publication_date":"2022-12-20","legal_status":"Granted"} US11529431B2 20 Dec, 2022 Granted 16 Mar, 2037
{"application_id":"120697","ingredient":"PERFLUTREN","trade_name":"DEFINITY","family_id":"aa0a3b1a16d34e1ca1af","publication_number":"US11857646B2","cleaned_patent_number":"11857646","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-03-16","publication_date":"2024-01-02","legal_status":"Granted"} US11857646B2 02 Jan, 2024 Granted 16 Mar, 2037
{"application_id":"120702","ingredient":"PERFLUTREN","trade_name":"DEFINITY","family_id":"aa0a3b1a16d34e1ca1af","publication_number":"US11925695B2","cleaned_patent_number":"11925695","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-03-16","publication_date":"2024-03-12","legal_status":"Granted"} US11925695B2 12 Mar, 2024 Granted 16 Mar, 2037
{"application_id":"62425","ingredient":"PERFLUTREN","trade_name":"DEFINITY","family_id":"aa0a3b1a16d34e1ca1af","publication_number":"US20220184237A1","cleaned_patent_number":"12161730","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-03-16","publication_date":"2024-12-10","legal_status":"Pending"} US12161730B2 10 Dec, 2024 Pending 16 Mar, 2037
{"application_id":"62430","ingredient":"PERFLUTREN","trade_name":"DEFINITY","family_id":"6a7410df45bc4eabb7f3","publication_number":"US10588988B2","cleaned_patent_number":"10588988","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-05-04","publication_date":"2020-03-17","legal_status":"Granted"} US10588988B2 17 Mar, 2020 Granted 04 May, 2037

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID Title Status Phase Conditions Start Date Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

View Complete Supplier List

Unlock access to all suppliers of Perflutren

✓ Access a comprehensive list of global suppliers
✓ Get information on each supplier
Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.

GreyB © 2025 Elixir. All rights reserved.